Evidence map›Paper›PMID 32282650›Full record

ArticleJournal of pediatric hematology/oncology2020

Primary Renal Ewing Sarcoma in Children and Young Adults.

Kathryn Bradford, Alexander Nobori, Brittany Johnson, Wendy Allen-Rhoades, Bindi Naik-Mathuria, Eduard H Panosyan, Moran Gotesman, Joseph Lasky, Jerry Cheng, Alan Ikeda and 3 more

Abstract readCase Reports
In one paragraph

Article in Journal of pediatric hematology/oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Kathryn BradfordDepartments of Pediatric Hematology-Oncology.
Alexander NoboriPathology.
Brittany JohnsonDivision of Pediatric Surgery.
Wendy Allen-RhoadesDepartment of Pediatric Oncology, Texas Children's Hospital, Baylor College of Medicine, Houston, TX.
Bindi Naik-MathuriaDivision of Pediatric Surgery.
Eduard H PanosyanDepartment of Pediatric Hematology and Oncology, Harbor-UCLA Medical Center, Torrance, CA.
Moran GotesmanDepartment of Pediatric Hematology and Oncology, Harbor-UCLA Medical Center, Torrance, CA.
Joseph LaskyDepartment of Pediatric Hematology and Oncology, Harbor-UCLA Medical Center, Torrance, CA.
Jerry ChengDepartment of Pediatric Hematology-Oncology/Pediatric BMT, Kaiser Permanente - Los Angeles Medical Center, Los Angeles.
Alan IkedaDepartment of Pediatric Hematology-Oncology, Children's Specialty Center of Nevada, Las Vegas, NV.
Jeffrey GoldsteinPathology.
Arun SinghHematology and Oncology, University of California, Los Angeles (UCLA).
Noah FedermanDepartments of Pediatric Hematology-Oncology.

Funding

Training in Developmental HematologyT32HL086345 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KOHN, DONALD B · 2007 to 2022
$3.8M
NHLBI NIH HHS T32 HL086345
6 · The paper itself

Abstract

The Ewing sarcoma family of tumors (ESFT) are high-grade small round blue cell malignancies traditionally presenting in children and adolescents. The most common site of primary disease is bone, though extraskeletal primary sites are well-recognized. We present 6 cases of primary ESFT of the kidney and 1 case of the adrenal gland. Patients were 11 to 18 years of age at diagnosis. Metastases at diagnosis were present in most cases (n=6). All patients underwent surgery, and most received radiation (n=5). Five patients relapsed after initial remission. Comprehensive review of the primary renal ESFT literature was used to analyze various factors, including age, sex, disease metrics, metastases at diagnoses, and overall survival in a total of 362 cases. Notably, while the general ESFT population has reported rates of metastasis at diagnosis of 20% to 25%, this rate in the renal ESFT population was 53% with a rate of 59% in adolescent and young-adult patients (11 to 24 y). Nodal disease at diagnosis was present in 24% of renal ESFT cases compared with 3.2% in patients with primary skeletal ESFT. While this malignant process may share histologic and molecular features with its bone and soft tissue counterparts, primary renal ESFT presentations seem to be more aggressive and have worse outcomes.

Indexed as

AdolescentChildFemaleHumansKidney NeoplasmsMaleSarcoma, Ewing

Identifiers

PMID32282650
PMCPMC7554078

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.